Compare EEFT & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EEFT | ACAD |
|---|---|---|
| Founded | 1994 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 4.3B |
| IPO Year | 1996 | 2000 |
| Metric | EEFT | ACAD |
|---|---|---|
| Price | $65.43 | $26.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 22 |
| Target Price | ★ $95.00 | $30.55 |
| AVG Volume (30 Days) | 527.9K | ★ 1.2M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 6.05 | ★ 69.12 |
| EPS | ★ 2.54 | 0.20 |
| Revenue | ★ $4,244,200,000.00 | $726,437,000.00 |
| Revenue This Year | $8.17 | $18.80 |
| Revenue Next Year | $5.97 | $11.70 |
| P/E Ratio | ★ $26.02 | $131.98 |
| Revenue Growth | 6.38 | ★ 40.45 |
| 52 Week Low | $62.50 | $19.69 |
| 52 Week High | $90.47 | $30.96 |
| Indicator | EEFT | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 38.77 | 40.47 |
| Support Level | $64.19 | $24.81 |
| Resistance Level | $75.32 | $27.80 |
| Average True Range (ATR) | 2.27 | 0.73 |
| MACD | -0.42 | -0.24 |
| Stochastic Oscillator | 14.05 | 11.14 |
Euronet Worldwide Inc is a provider of electronic financial transaction solutions. It offers payment and transaction processing and distribution solutions to financial institutions, retailers, service providers, and individual consumers. The company's product offerings include comprehensive ATM, POS, card outsourcing, card issuing, and merchant acquiring services, software solutions, money transfer services, etc. Its reportable operating segments are EFT Processing, epay, and Money Transfer. Maximum revenue is derived from its Money Transfer segment, which provides money transfer services across the world under the brand names Ria, AFEX, IME, and xe. Geographically, the company generates maximum revenue from the United States, followed by Germany, India, France, Greece, and other regions.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.